Oral cancer chemotherapy adherence and adherence assessment tools: A report from north central cancer group trial n0747 and a systematic review of the literature

Journal of Cancer Education

Volumn 28, Issue 4, 2013, Pages 770-776

  Patel, Krishna ^a   Foster, Nathan R ^a   Farrell, Ann ^a   Le Lindqwister, Nguyet Anh ^b   Mathew, Josy ^c   Costello, Brian ^a   Reynolds, John ^d   Meyers, Jeffrey P ^a   Jatoi, Aminah ^a,e  

^a MAYO CLINIC   (United States)

^b Illinois Oncol Res Assoc CCOP   (United States)

^c Park Nicollet Frauenshuh Cancer Center   (United States)

^d Sanford Bismarck Medical Center   (United States)

^e NONE   (United States)

Author keywords

Adherence; Adverse events; Oral chemotherapy; Over adherence

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

AGED; FEMALE; FOLLOW UP; HUMAN; LITERATURE; MALE; MEDICATION COMPLIANCE; METASTASIS; MOUTH TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MEDICATION ADHERENCE; MOUTH NEOPLASMS; PROGNOSIS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84888642519     PISSN: 08858195     EISSN: 15430154     Source Type: Journal    
DOI: 10.1007/s13187-013-0511-z     Document Type: Article

References (25)

1. http://chemoth.com/economics; last accessed March 20, 2013.
2. http://clinicaltrials.gov/ct2/show/NCT00891878?term=N0747+AND+jatoi& rank=1; last accessed March 20, 2013.
3. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-16
4. Sommers RM, Miller K, Berry DL (2012) Feasibility pilot on medication adherence and knowledge in ambulatory patients with gastrointestinal cancer. Oncol Nurs Forum 39:373-379
5. Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S (2012) Capecitabine non-adherence: exploration of magnitude, nature, and contributing factors. J Oncol Pharm Pract 18(3):333-342
6. Bordonaro S, Raiti F, Di Mari A et al (2012) Active home-based cancer treatment. J Multidiscip Healthc 5:137-143
7. Font R, Espinas JA, Gil-Gil M et al (2012) Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 107(8):1249-1256
8. Sadahiro S, Ohki S, Yamaguchi S et al (2000) Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan. Cancer Chemother Pharmacol 46(3):180-184
9. Winterhalder R, Hoesli P, Delmore G et al (2011) Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 80(1-2):29-33
10. Ziller V, Kalder M, Albert US et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3):431-436
11. Lee CR, Nicholson PW, Ledermann JA, Rustin GJS (1996) Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol 17(2):99-103
12. Waterhouse DM, Calzone KA, Mele C, Brenner DE (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189-1197
13. Ruddy KJ, Pitcher BN, Archer LE et al (2012) Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol 23(12):3075-3081
14. Saratsiotou I, Kordoni M, Bakogiannis C et al (2011) Treatment adherence of cancer patients to orally administered chemotherapy: insights from a Greek study using a self-reported questionnaire. J Oncol Pharm Pract 17(4):304-311
15. Clarke Hillyer G, Neugut AI, Crew KD et al (2012) Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. J Oncol Pract 8(5):e100-104
16. Simons S, Ringsdorf S, Braun M et al (2011) Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 19(7):1009-1018
17. Partridge AH, Archer L, Kornblith AB et al (2010) Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 28(14):2418-2422
18. Lee CR, Nicholson PW, Souhami ME et al (1993) Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 67(3):630-634
19. Thivat E, Van Praagh I, Belliere A et al (2013) Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors. Oncology 84(2):67-74
20. Spoelstra SL, Given BA, Given CW et al (2013) An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study. Cancer Nursing 36(1):18-28
21. Cartei G, Cartei F, Interlandi G et al (2000) Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23(2):181-184
22. Uematsu T, Nakashima M, Fujii M et al (1996) Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy. Eur J Clin Pharmacol 50(1-2):109-113
23. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56-66
24. Partridge AH, LaFountain A, Mayer E et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556-562
25. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602-606